31 results about "Long acting beta" patented technology

Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.

Compositions which comprise a combination of a salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane, and a long-acting phenylalkylamino beta₂-agonist are effective for the prevention and treatment of inflammatory or obstructive airways diseases.

A method of delivery of a combination therapy to the pulmonary system that includes providing a nebulizer and a fluid comprising a long-acting corticosteroid, a long-acting beta-agonist, and a long-acting anticholinergic in a pharmaceutically acceptable vehicle, and administering the solution to the patient using the nebulizer. The corticosteroid is budesonide, the beta-agonist is formoterol and the anticholinergic is tiotropium in a an aqueous solution, suspension or emulsion suitable for administration with the nebulizer.

Provided herein are pharmaceutical and cosmetic formulations and methods for regional adiposity reduction and treatment of body contour defects such as abdominal bulging; comprising an injectable formulation, said formulation comprising: an active ingredient that consists essentially of an adipose tissue-reducing amount of one or more lipophilic long-acting selective beta-2 adrenergic receptor agonists, or salts, solvates, or polymorphs thereof; and one or more subcutaneously acceptable inactive ingredients.

This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose, and its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases. More particularly, the invention relates to pharmaceutical composition for inhalation further comprising a ternary component. In addition, the present invention relates to novel pharmaceutical composition for inhalation based on combinations of long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, corticosteroids or a combination of two or more of them.

The invention discloses an aerosol containing muscarine receptor antagonist and beta 2 receptor stimulant, and a preparation method thereof. The aerosol contains a propulsive agent, long-acting beta 2 receptor stimulant particles, and long-acting muscarine antagonist particles; in LABA particles, by volume, the geometric particle size of 90% particles is smaller than 10<mu>m, and the geometric particle size of 50% particles is smaller than 4<mu>m or even smaller; the middle particle size of LAMA particles ranges from 500nm to 10<mu>m; the LAMA particles are particles composed of LAMA, calcium chloride, and a surfactant; or the LAMA particles are particles composed of LAMA and an excipient. 1 to 100<mu>g of the aerosol is sprayed in each time of pressing of a MDI (metered dose inhaler), and the amount of LABA or LAMA in the aerosol ranges from 0.02 to 2mg/mL. The advantages of the aerosol are that: delivery efficiency is relatively high, and the delivery dosage is stable in long term of storing.

The invention relates to a preparation method of an inhalation dry powder composition. The method comprises the following steps that 1, a lubricant and a medicinal carrier are subjected to first shearmixing to obtain a carrier compound; 2, the carrier compound in the step 1, a long-acting cholinergic receptor blocking agent and a long-acting beta receptor stimulant are subjected to second shear mixing, so that the inhalation dry powder composition is obtained.

The invention discloses an inhalable aerosol, a raw material composition thereof and preparation methods thereof. The raw material composition of the inhalable aerosol, disclosed by the invention, contains a medicinal active component and a propellant, wherein the medicinal active component contains a long-acting beta-receptor agonist and glucocorticoid; the propellant comprises tetrafluoroethane. The inhalable aerosol disclosed by the invention contains the raw material composition, a pressure container and a valve system. The inhalable aerosol uses the tetrafluoroethane as the propellant; during preparation, medicine particles are prepared by a supercritical method and a spray drying method, so that the inhalable aerosol with uniform particle distribution can be obtained; in the preparation method, the loss is low; in addition, the single dose of the inhalable aerosol is adjusted, so that the greenhouse gas amount of a product is effectively reduced.

A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta₂-adrenoceptor agonist, and a corticosteroid is provided.